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Introduction: The efficacy of perioperative statin therapy in decreasing postoperative morbidity in patients undergoing valve 
replacements and repairs is unknown. The aim of our study was to determine whether or not the literature supports the 
hypothesis that statins decrease postoperative atrial fibrillation (AF), and hence improve short-term postoperative outcomes in 
patients undergoing isolated cardiac valve surgery.
Method: We conducted a meta-analysis of studies on postoperative outcomes associated with statin therapy following isolated 
valve replacement or repair. The data was taken from published studies on valvular heart surgery patients. Participants were 
patients who underwent either isolated cardiac valve replacement or repair. Patients in the intervention group received statins 
prior to their surgery. Three databases were searched: Ovid Healthstar, 1966 to April 2012; Ovid Medline, 1946 to 31 May 2012; 
and Embase, 1974 to 30 May 2012. The meta-analysis was conducted using Review Manager® version 5.1.
Results: Statins did not decrease the incidence of postoperative AF in patients undergoing isolated cardiac valve surgery [odds 
ratio (OR) 1.19, 95% confidence interval (CI): 0.80– 1.77)], although there was significant heterogeneity for the outcome of 
postoperative AF (I2 55%, 95% CI: 27–72). Statins were associated with a decrease in 30-day mortality (OR 0.43, 95% CI: 0.24–0.75).
Conclusion: Although this meta-analysis suggests that chronic statin therapy did not prevent postoperative AF in unselected 
valvular heart surgical patients, the heterogeneity indicates that this outcome should be viewed with caution and further 
research is recommended.
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Introduction
Postoperative atrial fibrillation (AF) is a common occurrence in 
patients undergoing cardiac surgery requiring cardiopulmonary 
bypass,1 with an incidence ranging from 27–40% after mixed 
cardiac surgery [cohorts who underwent coronary artery bypass 
graft (CABG) surgery and/or valvular heart surgery]2,3 and 
37–50% for patients who underwent valvular surgery alone.4 AF 
is associated with an increase in both short and long-term 
mortality in cardiac surgical patients,2,5–7 as well as increased 
postoperative morbidity, i.e. a stroke, ventricular arrhythmias, 
myocardial infarction, heart failure, acute kidney injury, infection, 
neurocognitive impairment8,9 and prolonged hospitalisation.2,5,6,7,9 
The prevention of postoperative AF has been associated with 
improved postoperative outcomes.2
The inflammation and oxidative stress associated with both 
cardiac surgery and cardiopulmonary bypass may drive the 
development of AF following cardiac surgery. The anti-
inflammatory,2,10 antioxidative 2,6,10,11 and direct antiarrhythmic 
effects mediated by cell membrane ion channel stabilisation9 of 
statin therapy may decrease postoperative AF. This effect of 
statin therapy was confirmed in a meta-analysis of randomised 
controlled trials of statin therapy in mixed cardiac surgery 
cohorts.12 However, what is uncertain is whether or not statin 
therapy decreases AF and possibly mortality in valvular heart 
surgery alone.
In contrast, the role of statins in patients undergoing CABG 
surgery was clearly defined by a 2011 task force of the American 
College of Cardiology Foundation and the American Heart 
Association. Based on extensive data demonstrating that statin 
therapy improves outcomes in patients with established 
coronary artery disease, the task force recommended that all 
patients undergoing CABG surgery receive perioperative statins 
unless contraindicated (class 1 recommendation, level of 
evidence A).13 Therefore, all patients undergoing CABG surgery 
should receive perioperative statin therapy. Hence, the use of 
statins to prevent AF in these patients is not debatable as statins 
are associated with survival benefit in these patients.
However, statins are not currently indicated for the prevention of 
AF or mortality in patients undergoing isolated valvular heart 
surgery alone as it is unknown whether or not statin therapy in 
these patients decreases postoperative AF and mortality.
In order to address this limitation in the current literature, we 
embarked on a systematic review and meta-analysis of the efficacy 
of perioperative statin therapy in preventing postoperative AF in 
patients undergoing isolated cardiac valve surgery.
Method
Using the patient, intervention, comparison, outcome and time 
(PICOT) question structure,14 we posed the following research 
question: “Do statins prevent postoperative AF in patients 
undergoing isolated cardiac valve surgery?” In order to answer this 
question, we conducted a systematic review and meta-analysis of 
studies which documented the postoperative outcomes of 
patients who had received statins and undergone isolated cardiac 
valve replacement or repair. We defined acute statin therapy as 
statins which were started in the preoperative period specifically 
with the intention of preventing surgical morbidity. Chronic statin 
therapy referred to patients already taking statins in the 
perioperative period for the management of other pre-existing 
co-morbidities.
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Study end-points
Postoperative AF was the primary outcome of interest. Secondary 
outcomes included 30-day mortality, non-fatal myocardial 
infarction and strokes. The protocol for this meta-analysis was not 
registered. As this meta-analysis comprised retrospective, 
observational studies, the Meta-analysis of Observational Studies 
in Epidemiology guidelines were adhered to.15
Study identification and selection
Studies were identified by searching electronic databases and 
scanning article reference lists. Three databases were searched: 
Ovid Healthstar, 1966 to April 2012; Ovid Medline, 1946 to 31 May 
2012; and Embase, 1974 to 30 May 2012. The following search 
terms were used: 
•  “Cardiac surgery”, “coronary artery bypass”, “coronary artery 
bypass graft” and “CABG”.
•  “Statin” and “statins”.
•  “Randomised controlled trial”, “randomised” and “placebo”.
The search was limited to the English language, and to human 
and adult studies. Duplicated studies were removed, leaving a 
total of 296 citations. The search was updated on 2 April 2013 and 
a further 143 citations were found.
Two reviewers screened the abstracts independently and 
selected the relevant citations. Disputes were resolved by 
consensus between the reviewers. When agreement could not be 
reached, a third reviewer made the final eligibility decision. Full 
papers for the relevant citations were obtained. Papers were only 
included in the final data analysis if one of the study outcomes 
was AF. If papers included a mixed cardiac surgical procedure 
cohort, the data on valvular surgical patients were either 
extracted from the paper or obtained through correspondence 
with the authors.
Data extraction
A predetermined data form was used to extract data from each 
study on the presence or absence of perioperative statin 
administration and the associated postoperative outcomes of 
interest. Data was extracted on the following characteristics of 
statin administration: the type of statin given, acute versus 
chronic administration, and the duration of pre- and postoperative 
statin therapy. Data was also extracted on preoperative AF. Where 
possible, data was obtained on the patient demographics for 
each study cohort, i.e. ischaemic heart disease, cerebral vascular 
disease, renal dysfunction, hypertension, diabetes mellitus, age 
and sex.
The Newcastle-Ottawa Scale (NOS16) for cohort studies was used 
to assess the cohort study quality (Table 1). The Preferred 
Reporting Items for Systematic Reviews and Meta-analyses 
guidelines were followed.17
Data analysis
The confidence intervals (CIs) of the reported morbidities were 
calculated for each study to assess the comparability of the 
studies. If the CIs did not overlap for associated co-morbidities, 
the studies were considered to be poorly comparable.
The meta-analysis was conducted using Review Manager® version 
5.1 (The Nordic Cochrane Centre, The Cochrane Collaboration, 
Copenhagen, Denmark, 2011). Heterogeneity between the 
studies was assessed using I2 analysis. Heterogeneity describes 
the between-study variance, and if significant, suggests that the 
true effects between the studies included in the meta-analysis 
differ,18 meaning that more conservative meta-analyses should be 
conducted using random-effects models. The 95% CI was 
calculated for I2, using the formula of Higgins and Thompson.18 
Random (DerSimonian and Laird modification) or fixed effects 
(Cochran-Mantel-Haenszel) models were used based on the 
presence (upper CI of I2 > 25%) or the absence (upper CI of I2 < 
25%) of significant heterogeneity between the studies, 
respectively. Pooled dichotomous outcomes were reported as 
the odds ratio (OR) and 95% CI.
In the event of statin therapy not being associated with a reduction 
in postoperative AF in the meta-analysis, we planned to conduct a 
power analysis to determine if the sample size was adequate. The 
sample size was considered to be adequate if it could demonstrate 
a 25% relative risk reduction (RRR) in AF in the statin group 
compared to the event rate in the control group of the meta-
analysis. The sample size was calculated using the “difference in 
proportions” for equal-sized groups.19 So with a control group 
event rate of 24.3% for postoperative AF, as in this meta-analysis, a 
25% RRR would give an expected event rate in the intervention 
group (statins) of 18.3%.
Results
The search identified 439 studies. References of the review articles 
and meta-analyses from the original search were also checked for 
relevant citations, and a further 24 studies were identified.
After examination of the abstracts, 74 full-text articles were 
assessed for eligibility, of which 58 papers were excluded. The 
reasons for exclusion of the 58 articles were: 
Table 1: The Newcastle Ottawa Scale for cohort studies,16 as adapted for use in this meta-analysis
Category Criteria Maximum number of stars
Selection 1. Is the cohort representative of cardiac surgery patients undergoing valve replacement and repair? 1
2. Are the patients on statins from the same cardiac surgical cohort as the control group used in the study? 1
3. Was screening for postoperative atrial fibrillation routine for all of the study patients? 1
4. Were patients with preoperative atrial fibrillation reliably excluded from the postoperative atrial fibrillation 
cohort?
1
Comparability 1. The data extracted for use in this meta-analysis should only include cardiac valve replacement and repair 
patients.
1
2. The age, gender and prevalence of ischaemic heart disease, diabetes mellitus, strokes and renal dysfunction 
should be comparable between studies. The exclusion of co-morbidities is undesirable.
1
Outcome 1. The assessment must be independently blinded, record linked or from the secure records. 1
2. The follow-up must be long enough for an outcome to occur, and is defined as 30 days. 1
3. The follow-up must be adequate. It is defined as a complete follow-up, or a description of the withdrawn pa-
tients to ensure that they were not secondary to any of the outcomes being investigated.
1
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•  Thirty-two were review papers, editorials or guideline 
articles.
•  Eleven were meta-analyses.
•  AF was not included as an outcome in four studies.
•  Patients with valvular heart disease were not included in the 
cardiac surgery patient cohort in four studies.
•  Statins were not used in four studies.
•  The results were not yet published for one study.
•  Surgical ablation, as well as statins, were used to control 
postoperative AF in one study.
•  The cardiac surgical cohort contained patients undergoing 
combine aortic valve replacement and CABG procedures in 
one study.
• There was a duplicate dataset publication.
The authors of the remaining 16 studies were contacted.3,7,9,20–32 
Eight authors replied to our emails,3,7,9,26–28,31,32 but only five were 
able to provide the required information,3,7,26,28,32 leaving five 
studies for potential inclusion in a quantitative analysis. However, 
in the study by Kourliouros et al.,7 patients were randomised to 
receive either high-dose (80 mg) or low-dose (10 mg) atorvastatin 
for seven days prior to cardiac surgery, and as there was no statin-
naïve group, i.e. control group, this study was also excluded 
(Figure 1).
All four remaining studies were retrospective cohort studies3,26,28,32  
(Table 2). Two of the studies included patients from mixed surgical 
cohorts of CABG and valvular heart surgery, where the authors 
provided specific quantitative data for the patients undergoing 
valvular heart surgery only.3,28 Postoperative AF was either a primary3 or 
secondary outcome26,28,32 in the included studies. The demographics of 
the patients in the included studies are shown in Table 3. The CIs did not 
overlap with regard to the prevalence of congestive cardiac failure and 
diabetes between the studies. Hypertension occurred significantly less 
in the study by Allou et al., compared to the other studies. Therefore, 
comparability was poor across the studies. The characteristics of the 
statin therapy and preoperative cardiac rhythms are shown in Table 4. 
The NOS score16 is shown in Table 5. The studies generally showed 
reasonable selection and outcome data according to our criteria, 
although comparability was poor across all studies.
The studies included in this meta-analysis contained only patients 
on chronic statin therapy. The duration of preoperative statin 
therapy was poorly defined, and extended from two weeks to in 
excess of six months prior to surgery. The study by Allou et al.26  
provides the shortest preoperative statin therapy inclusion criteria 
of at least two weeks before surgery, while Billings et al.28 reports 
patients on chronic statin therapy, only and does not define 
“chronic”. Vaduganathan et al.32 includes patients who have been 
on statins for at least six months prior to surgery, while Helgadottir 
et al.3 does not describe the duration of the preoperative statin use.
This meta-analysis included 720 valvular heart surgical patients 
who received chronic statin therapy, i.e. the intervention group, 
and 796 patients who did not receive statin therapy, i.e. the 
control group. Therefore, this meta-analysis was considered to 
be adequately powered for the primary outcome as we required 
706 patients per group in order to demonstrate a 25% RRR in 
the primary outcome of postoperative AF, based on a control 
event rate of 24.4%. The meta-analysis showed that statins were 
not associated with a decrease in postoperative AF (OR 1.19, 
95% CI: 0.80–1.77) in patients undergoing isolated valvular 
Table 2: The study characteristics
Reference Type of study Primary outcome Secondary outcome
Allou et al.26 Retrospective 30-day mortality Myocardial infarction, cardiogenic shock, acute kidney injury, a 
stroke and severe forms of sepsis 
Billings et al.28 Retrospective Acute kidney injury Atrial fibrillation, time to extubation, length of stay and 
mortality 
Vaduganathan et al.32 Retrospective and propensity matched Short- and mid-term mortality Re-admission rates, length of hospital stay, re-operation, a 
stroke, prolonged ventilation, pneumonia, renal failure, heart 
block and atrial fibrillation, 
Length of hospital stay
Helgadottir et al.3 Retrospective Atrial fibrillation 30-day mortality, wound infection, urinary tract infection, 
pneumonia, a stroke, mediastinitis, endocarditis, myocardial 
infarction, acute kidney injury, reoperation, sternal dehiscence, 
acute respiratory distress syndrome, multi-organ failure and 
bleeding
Figure 1: Flow diagram showing the literature search, as per the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
guidelines17
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Discussion
The main finding of this meta-analysis was that chronic 
perioperative statin administration was associated with a 
reduction in 30-day mortality, but not postoperative AF, following 
isolated valvular heart surgery. However, significant heterogeneity 
was associated with the efficacy of statin therapy for postoperative 
AF, which suggests the need for caution in the interpretation of 
these findings. Furthermore, this meta-analysis showed that 
currently, there are no data to inform on the efficacy of acute 
statin therapy in isolated valvular heart surgery.
If chronic statin therapy does not prevent postoperative AF in 
unselected valvular surgical patients, then it is unlikely that it will 
decrease other morbidities associated with postoperative AF. 
Therefore, the perioperative survival benefit associated with 
statin therapy in this meta-analysis is most likely driven by the 
original indication for primary or secondary cardiovascular 
intervention in the patients in this meta-analysis.
This meta-analysis was underpowered for the secondary 
outcomes of myocardial infarction and strokes, because only 
heart surgery. Statins were associated with a decrease in 30-day 
mortality (OR 0.43, 95% CI: 0.24–0.75) (Figures 2 and 3). There 
was significant heterogeneity for the outcome of postoperative 
AF (I2 55%, 95% CI: 27–72%), and possible heterogeneity for 
30-day mortality (I2 0%, 95% CI: 0–72%). The significant 
heterogeneity associated with postoperative AF suggests that 
although the sample size suggests an adequacy of power for 
this meta-analysis, the significant variation in the true effect 
between the included studies may mean that this meta-analysis 
was actually underpowered with respect to the outcome of 
interest.
A meta-analysis of postoperative myocardial infarction was 
not conducted as only two studies provided data on this 
outcome, and the number of events was small, i.e. five events 
in the statin group and three events in the control group. 
Similarly, a meta-analysis of postoperative strokes was not 
conducted as three studies provided data on this outcome, 
with nine events in the statin group and seven events in the 
control group.
Table 3: Patient demographics of the cohorts included in the meta-analysis*
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AVR: aortic valve replacement, C: control, CABG: coronary artery bypass graft, CAD: coronary artery disease, CCF: congestive cardiac failure, CVD: 
cerebrovascular disease, DM: diabetes mellitus, HT: hypertension, n: number, NR: not reported, OPCAB: off-pump coronary artery bypass graft, RD: renal 
dysfunction, S: statin
*: Values are number (proportion), mean (± 1 standard deviation) or median range
**: Propensity matched
Table 4: Characteristics of the statin administration
References Preoperative 
statin










Allou et al.26 Yes Any Unknown Chronic ≥ 2 weeks Unknown
Billings et al.28 Yes Any No AF Chronic Unknown Unknown
Vaduganathan  
et al.32
Yes Any Unknown Chronic ≥ 6 months Unknown
Helgadottir et al.3 Yes Any No AF Chronic Unknown Unknown
AF: atrial fibrillation
Table 5: Quality of the studies included in the meta-analysis
References Follow-up period The Newcastle Ottawa Scale16
Selection Comparability Outcome
Allou et al.26 30 days ** * ***
Billings et al.28 In hospital **** * **
Vaduganathan et al.32 Mean follow-up (32.9 months) *** * ***
Helgadottir et al.3 Mean follow-up (60 months) *** * ***
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aortic valve replacement may predispose them to persistence of 
postoperative AF. This may obviate the theoretical protective effects 
that statins may have on postoperative AF in these patients. 
A recently published meta-analysis on statins in patients undergoing 
coronary revascularisation and aortic valve surgery by Kuhn et al.,34 
which included the papers considered in this meta-analysis, adds no 
further evidence on AF following aortic valve replacement.
Secondly, the presence of other antiarrhythmic medication 
may overshadow the efficacy of statin therapy in preventing 
postoperative AF. Patients who were on antiarrhythmic drugs 
preoperatively were included in the studies selected for the meta-
analysis.
Finally, data were not obtained on patients’ compliance with the 
statin therapy, and it is possible that they may have temporarily 
been withdrawn from statin therapy in the early postoperative 
period.
Limitations
A number of limitations were associated with this meta-analysis. 
Firstly, we were unable to obtain data specifically on isolated 
valvular heart surgical patients from eight studies. Had we been 
able to obtain this information it might have made our findings 
studies that included AF as an outcome were included in this 
meta-analysis, and hence the number of outcomes for nonfatal 
myocardial infarction 3.28 and strokes3,26,32 were few.
The lack of protection for postoperative AF associated with chronic 
statin therapy in this meta-analysis may be due to other factors. 
Firstly, we were unable to separate patients undergoing aortic valve 
replacement from those undergoing mitral valve replacement. It is 
likely, based on the demographics of the patients in the included 
studies (Table 3), that aortic valve replacement predominated. We 
know that patients with isolated aortic valve disease tend to be older 
and have more concomitant co-morbidities, such as diabetes and 
hypertension. As the average age of the patients in the meta-analysis 
was 60  years and older, and there was a significant incidence of 
hypertension and diabetes, it is likely that isolated valve replacements 
for aortic valve disease predominated in this meta-analysis. This is 
consistent with the data presented by Vaduganathan et al.32  
The patients taking statins in their cohort were significantly older, 
and had higher rates of co-morbid and chronic disease, e.g. 
hyperlipidaemia, hypertension, diabetes, cerebrovascular disease, 
chronic lung disease, coronary artery disease and peripheral vascular 
disease. While it is possible that the incidence of postoperative AF is 
higher in mitral valve replacement than in aortic valve replacement,33 
the burden of underlying co-morbid diseases in patients undergoing 
Figure 3: Meta-analysis of the efficacy of statin therapy in preventing 30-day mortality in valvular heart surgery patients
Note: Heterogeneity: Tau2 = 0.00, chi-square test*** = 1.54, degrees of freedom = 3 (p = 0.67), I2 = 0%
Test for overall effect: Z-test  = 2.84 (p = 0.004)
CI: confidence interval, I2: the percentage of variation across studies that is due to heterogeneity rather than chance, M-H: Mantel-Haenszel test (compares 
the odds ratios of several 2 x 2 tables), p: probability
*: Number of patients developing the outcome of interest
**: Total number of patients in the statin or control group
***: Test for the significance of Cochran’s Q test (p < 0.1 is considered to be significant)
Figure 2: Meta-analysis of the efficacy of statin therapy in preventing postoperative atrial fibrillation in valvular heart surgery patients
Note: Heterogeneity: Tau2 = 0.08, chi-square test*** = 6.60, degrees of freedom = 3 (p = 0.09), I2 = 55%
 Test for overall effect: Z-test = 0.86 (p = 0.39)
CI: confidence interval, I2: the percentage of variation across studies that is due to heterogeneity rather than chance, M-H: Mantel-Haenszel test (compares 
the odds ratios of several 2 x 2 tables), p: probability 
*: Number of patients developing the outcome of interest
**: Total number of patients in the statin or control group
***: Test for the significance of Cochran’s Q test (p < 0.1 is considered to be significant)
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more robust. This is important as although our meta-analysis may 
have been adequately powered for our primary outcome, the 
significant heterogeneity associated with postoperative AF 
suggests that the results cannot be considered to be conclusive.
Secondly, there were no randomised controlled trials of acute 
perioperative statin therapy. The beneficial pleiotrophic effects of 
statin therapy occur as early as 24 hours,35 and this is the rationale 
behind the on table administration of statins in CABG statin-naïve 
patients.13 It is possible that acute statin therapy given 
preoperatively in statin-naïve isolated valvular surgical patients 
might decrease postoperative AF. This meta-analysis could not 
address this issue, as there were no data on this topic. There 
remains compelling evidence to test this hypothesis in a 
randomised controlled trial.12
Finally, it was impossible to determine the type and dose of 
statins administered. It is possible that high-dose statin therapy 
might confer more protection against postoperative AF. The 
potential difference in dose and duration of statin therapy may 
partly explain the heterogeneity seen in the meta-analysis of 
postoperative AF.
Conclusion
Although, this meta-analysis suggests that chronic statin 
therapy may prevent mortality, but not postoperative AF, in 
unselected valvular heart surgical patients, the heterogeneity 
of the meta-analysis and the missing data decreased our 
certainty in these data. Further research is necessary to 
adequately address this topic. We recommend that patients on 
chronic statin therapy continue this therapy during valvular 
heart surgery as it is associated with improved survival. 
Currently, there are no data on the efficacy of acute 
perioperative statin therapy in decreasing postoperative AF 
following valvular heart surgery.
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